Alliance Global Partners lowered shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) from a buy rating to a neutral rating in a research note released on Monday morning, The Fly reports. The brokerage currently has $4.50 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $11.00.
Several other brokerages have also recently commented on ALIM. HC Wainwright raised their price target on shares of Alimera Sciences from $8.00 to $9.00 and gave the company a buy rating in a research report on Thursday, July 28th. StockNews.com began coverage on shares of Alimera Sciences in a research note on Monday. They set a hold rating on the stock.
Alimera Sciences Stock Performance
NASDAQ:ALIM opened at $4.19 on Monday. The stock has a market capitalization of $29.34 million, a P/E ratio of -1.59 and a beta of 1.38. The company has a 50 day moving average price of $5.21 and a 200 day moving average price of $5.64. Alimera Sciences has a fifty-two week low of $3.94 and a fifty-two week high of $7.92.
Hedge Funds Weigh In On Alimera Sciences
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.